A Look At Merck's Late Stage Pharmaceuticals Pipeline |
| December 12, 2018 | December 2018 Bond Updates |
|
Merck (NYSE:MRK) has a strong late stage pharmaceuticals pipeline, and it could be worth as much as $13 billion, or over 6% of its current market value, according to our estimates. Several drugs in the pipeline are capable of generating more than $1 billion in peak sales. Merck’s drug pipeline... |
| View more at: https://www.forbes.com/sites/greatspeculations/2018/12/11/a-look-at-mercks-late-stage-pharmaceuticals-pipeline/ |
| Related News |